News | June 08, 2024
Lupin completes acquisition of two brands from Sanofi in Europe and Canada
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
DCGI has also granted permission to manufacture and market FDF of Cefepime and Enmetazobactam as a dry powder injectable
Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders
This novel recombinant has been developed and is a patented novel recombinant Human Albumin 20% process
The state-of-the-art facility is equipped with best-in-class equipment and control systems
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
This significant achievement includes an initial order from GCPL valued at a substantial Rs. 2.4 crore
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
Subscribe To Our Newsletter & Stay Updated
